## **Core Concept**
Multiple myeloma is a type of hematological malignancy characterized by the proliferation of malignant plasma cells in the bone marrow. Immunoglobulins, also known as antibodies, are produced by plasma cells and play a crucial role in the immune response. In multiple myeloma, a single clone of plasma cells proliferates and produces a single type of immunoglobulin.

## **Why the Correct Answer is Right**
The correct answer, **IgG**, is the immunoglobulin most commonly involved in multiple myeloma. Approximately 50-60% of patients with multiple myeloma have IgG myeloma, which means their malignant plasma cells produce IgG antibodies. IgG is the most abundant immunoglobulin in the serum and provides long-term immunity against infections. The production of a single type of IgG antibody (monoclonal gammopathy) can lead to various clinical complications, including hyperviscosity syndrome, kidney damage, and increased susceptibility to infections.

## **Why Each Wrong Option is Incorrect**
* **Option A:** is incorrect because IgM is more commonly associated with Waldenström's macroglobulinemia, another type of lymphoproliferative disorder.
* **Option B:** is incorrect because IgA myeloma accounts for about 20% of multiple myeloma cases, making it less common than IgG myeloma.
* **Option D:** is incorrect because IgE is rarely, if ever, associated with multiple myeloma, and **Option C:** (not explicitly listed but implied as the remaining choice) would be incorrect based on the context provided.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the type of immunoglobulin involved in multiple myeloma can influence the clinical presentation and complications. For example, IgG and IgA myelomas are more likely to cause kidney damage and anemia, while IgM myeloma can cause hyperviscosity syndrome due to its high molecular weight.

## **Correct Answer:** . IgG